Overall, in a translational approach, we demonstrate that ex vivo activin-A treatment endows human lung tumor-infiltrating CD4+ T cells with a less exhausted phenotype and concomitantly boosts their immunostimulatory capacity towards autologous CD4+ and CD8+ T cells, mimicking its anti-tumorigenic effects observed in the mouse lung cancer models. This evidence concerns the gene CD4 and lung cancer.